Annual Cash & Cash Equivalents
$29.92 M
-$11.64 M-28.01%
31 December 2023
Summary:
Cognition Therapeutics annual cash & cash equivalents is currently $29.92 million, with the most recent change of -$11.64 million (-28.01%) on 31 December 2023. During the last 3 years, it has fallen by -$24.80 million (-45.32%). CGTX annual cash & cash equivalents is now -45.32% below its all-time high of $54.72 million, reached on 31 December 2021.CGTX Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Cash And Cash Equivalents
$22.01 M
-$6.52 M-22.86%
30 September 2024
Summary:
Cognition Therapeutics quarterly cash and cash equivalents is currently $22.01 million, with the most recent change of -$6.52 million (-22.86%) on 30 September 2024. Over the past year, it has dropped by -$7.91 million (-26.44%). CGTX quarterly cash and cash equivalents is now -59.78% below its all-time high of $54.72 million, reached on 31 December 2021.CGTX Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
CGTX Cash And Cash Equivalents Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | - | -26.4% |
| 3 y3 years | -45.3% | -59.8% |
| 5 y5 years | +935.4% | - |
CGTX Cash And Cash Equivalents High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -45.3% | at low | -59.8% | at low |
| 5 y | 5 years | -45.3% | +935.4% | -59.8% | +324.2% |
| alltime | all time | -45.3% | +935.4% | -59.8% | +324.2% |
Cognition Therapeutics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $22.01 M(-22.9%) |
| June 2024 | - | $28.53 M(-17.7%) |
| Mar 2024 | - | $34.67 M(+15.9%) |
| Dec 2023 | $29.92 M(-28.0%) | $29.92 M(-9.2%) |
| Sept 2023 | - | $32.97 M(-11.3%) |
| June 2023 | - | $37.19 M(-4.2%) |
| Mar 2023 | - | $38.81 M(-6.6%) |
| Dec 2022 | $41.56 M | $41.56 M(-10.8%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2022 | - | $46.61 M(+1.8%) |
| June 2022 | - | $45.77 M(-11.1%) |
| Mar 2022 | - | $51.51 M(-5.9%) |
| Dec 2021 | $54.72 M(+954.6%) | $54.72 M(+558.5%) |
| Sept 2021 | - | $8.31 M(-26.5%) |
| June 2021 | - | $11.30 M(-15.5%) |
| Mar 2021 | - | $13.37 M(+157.7%) |
| Dec 2020 | $5.19 M(+79.6%) | $5.19 M |
| Dec 2019 | $2.89 M | - |
FAQ
- What is Cognition Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Cognition Therapeutics?
- What is Cognition Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Cognition Therapeutics?
- What is Cognition Therapeutics quarterly cash and cash equivalents year-on-year change?
What is Cognition Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of CGTX is $29.92 M
What is the all time high annual cash & cash equivalents for Cognition Therapeutics?
Cognition Therapeutics all-time high annual cash & cash equivalents is $54.72 M
What is Cognition Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of CGTX is $22.01 M
What is the all time high quarterly cash and cash equivalents for Cognition Therapeutics?
Cognition Therapeutics all-time high quarterly cash and cash equivalents is $54.72 M
What is Cognition Therapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, CGTX quarterly cash and cash equivalents has changed by -$7.91 M (-26.44%)